Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder

Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder

LBA-006: BEACON CRC: A Randomized, 3-Arm, Phase-3 Study of Encorafenib and Cetuximab With or Without Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer
Scott Kopetz, et al.

SLIDES

The conclusion from authors abstract:

In the BEACON CRC study, the combination of ENCO+BINI+CETUX improved OS and ORR in patients with BRAF V600E-mutant mCRC when compared with current standard of care chemotherapy and had a safety profile consistent with the known safety profile of each agent. This targeted therapy regimen should be a new standard of care for this patient population.

 

P-400: ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Axel Grothey, et al.

The conclusion from authors abstract:

Approximately 90 patients are planned to be enrolled in 10 countries worldwide and recruitment is ongoing.  Clinical Trial Information   NCT03693170.

 

P-099: Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients

E Samalin , et al. LINK TO POSTER

The conclusion from authors abstract:

Conclusion: FOLFIRINOX plus cetuximab in initially unresectable mCRC patients is feasible. Further studies are needed to confirm the efficacy, especially in BRAF mutated tumors.



LBA-007: Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC
Chiara Cremolini, et al.

The conclusion from authors abstract:

Upfront FOLFOXIRI/bev followed by the pre-planned reintroduction of the same agents after PD significantly prolonged PFS2 and OS when compared with the pre-planned sequential administration of FOLFOX/bev and FOLFIRI/bev in unresectable mCRC patients. Treatment effect is consistent across analysed clinical and molecular subgroups, with potentially increased benefit among patients with a right-sided and/or a RAS or BRAF mutant tumor and in particular with ECOG PS 0.

 

O-025: A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients
Filippo Pietrantonio, et al.

The conclusion from authors abstract:

TMZ is an old drug with activity in MGMT-methylated mCRC and its use should be explored by phase 3 trials restricting the molecular selection to MGMT-negative +/-MGMT % hyper-methylated tumors.

 

O-026: Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)
Guillem Argiles, et al.

The conclusion from authors abstract:

Though REARRANGE did not meet its primary endpoint of improving REG global tolerability in either RD or ID arms, flexible dosing showed numerical improvement on relevant AEs like fatigue, HFSR and hypertension, without jeopardizing efficacy. These findings support the use of REG flexible dosing as an alternative option.

 

PD-013: RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

Sunakawa Y. et al. LINK TO POSTER

The conclusion from authors abstract:

Our study demonstrated that mCRC patients with RAS mutations in ctDNA at baseline have a shorter survival outcome when receiving rechallenge treatments with irinotecan plus anti-EGFR antibody, even if they were sensitive to the first-line anti-EGFR antibody-containing chemotherapy. Updated results will be presented at the meeting.

 

P-141: Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment

C Raimondi, et al.

The conclusion from authors abstract:

We propose a hypothetical algorithm which accounted for the transient disappearance of RAS-mutant clones over time, which might extend the continuum of care of mutant RAS colorectal cancer patients through the delivery of a further line of therapy. We further investigated relapse-associated mutated key genes in mCRC treated with EGFR inhibitors. The persistent absence of RAS mutations at relapse might lead to the identification of additional oncogenic driver mutations as potential targets for future therapeutic strategies.